453 related articles for article (PubMed ID: 21098971)
21. Diagnosing prodromal Alzheimer's disease: role of CSF biochemical markers.
Parnetti L; Lanari A; Silvestrelli G; Saggese E; Reboldi P
Mech Ageing Dev; 2006 Feb; 127(2):129-32. PubMed ID: 16274728
[TBL] [Abstract][Full Text] [Related]
22. CSF-tau and CSF-Abeta(1-42) in posterior cortical atrophy.
Baumann TP; Duyar H; Sollberger M; Kuhle J; Regeniter A; Gomez-Mancilla B; Schmidtke K; Monsch AU
Dement Geriatr Cogn Disord; 2010; 29(6):530-3. PubMed ID: 20606434
[TBL] [Abstract][Full Text] [Related]
23. MRI and CSF studies in the early diagnosis of Alzheimer's disease.
de Leon MJ; DeSanti S; Zinkowski R; Mehta PD; Pratico D; Segal S; Clark C; Kerkman D; DeBernardis J; Li J; Lair L; Reisberg B; Tsui W; Rusinek H
J Intern Med; 2004 Sep; 256(3):205-23. PubMed ID: 15324364
[TBL] [Abstract][Full Text] [Related]
24. Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study.
Lewczuk P; Kornhuber J; Vanderstichele H; Vanmechelen E; Esselmann H; Bibl M; Wolf S; Otto M; Reulbach U; Kölsch H; Jessen F; Schröder J; Schönknecht P; Hampel H; Peters O; Weimer E; Perneczky R; Jahn H; Luckhaus C; Lamla U; Supprian T; Maler JM; Wiltfang J
Neurobiol Aging; 2008 Jun; 29(6):812-8. PubMed ID: 17239996
[TBL] [Abstract][Full Text] [Related]
25. Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease.
Hansson O; Buchhave P; Zetterberg H; Blennow K; Minthon L; Warkentin S
Neurobiol Aging; 2009 Feb; 30(2):165-73. PubMed ID: 17646035
[TBL] [Abstract][Full Text] [Related]
26. Cerebrospinal fluid amyloid beta(1-42) levels in the mild cognitive impairment stage of Alzheimer's disease.
Maruyama M; Arai H; Sugita M; Tanji H; Higuchi M; Okamura N; Matsui T; Higuchi S; Matsushita S; Yoshida H; Sasaki H
Exp Neurol; 2001 Dec; 172(2):433-6. PubMed ID: 11716567
[TBL] [Abstract][Full Text] [Related]
27. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
[TBL] [Abstract][Full Text] [Related]
28. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.
Fagan AM; Roe CM; Xiong C; Mintun MA; Morris JC; Holtzman DM
Arch Neurol; 2007 Mar; 64(3):343-9. PubMed ID: 17210801
[TBL] [Abstract][Full Text] [Related]
29. Prediction of Alzheimer's disease using a cerebrospinal fluid pattern of C-terminally truncated beta-amyloid peptides.
Höglund K; Hansson O; Buchhave P; Zetterberg H; Lewczuk P; Londos E; Blennow K; Minthon L; Wiltfang J
Neurodegener Dis; 2008; 5(5):268-76. PubMed ID: 18309230
[TBL] [Abstract][Full Text] [Related]
30. Amyloid-β oligomers in cerebrospinal fluid are associated with cognitive decline in patients with Alzheimer's disease.
Santos AN; Ewers M; Minthon L; Simm A; Silber RE; Blennow K; Prvulovic D; Hansson O; Hampel H
J Alzheimers Dis; 2012; 29(1):171-6. PubMed ID: 22214781
[TBL] [Abstract][Full Text] [Related]
31. CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study.
Li G; Sokal I; Quinn JF; Leverenz JB; Brodey M; Schellenberg GD; Kaye JA; Raskind MA; Zhang J; Peskind ER; Montine TJ
Neurology; 2007 Aug; 69(7):631-9. PubMed ID: 17698783
[TBL] [Abstract][Full Text] [Related]
32. CSF biomarkers predict rate of cognitive decline in Alzheimer disease.
Kester MI; van der Vlies AE; Blankenstein MA; Pijnenburg YA; van Elk EJ; Scheltens P; van der Flier WM
Neurology; 2009 Oct; 73(17):1353-8. PubMed ID: 19858456
[TBL] [Abstract][Full Text] [Related]
33. Cerebrospinal fluid neuron-specific enolase: a further marker of Alzheimer's disease?
Palumbo B; Siepi D; Sabalich I; Tranfaglia C; Parnetti L
Funct Neurol; 2008; 23(2):93-6. PubMed ID: 18671910
[TBL] [Abstract][Full Text] [Related]
34. Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease.
Wagner M; Wolf S; Reischies FM; Daerr M; Wolfsgruber S; Jessen F; Popp J; Maier W; Hüll M; Frölich L; Hampel H; Perneczky R; Peters O; Jahn H; Luckhaus C; Gertz HJ; Schröder J; Pantel J; Lewczuk P; Kornhuber J; Wiltfang J
Neurology; 2012 Feb; 78(6):379-86. PubMed ID: 22238414
[TBL] [Abstract][Full Text] [Related]
35. CSF phosphorylated tau protein and mild cognitive impairment: a prospective study.
Arai H; Ishiguro K; Ohno H; Moriyama M; Itoh N; Okamura N; Matsui T; Morikawa Y; Horikawa E; Kohno H; Sasaki H; Imahori K
Exp Neurol; 2000 Nov; 166(1):201-3. PubMed ID: 11031097
[TBL] [Abstract][Full Text] [Related]
36. CSF APPs alpha and phosphorylated tau protein levels in mild cognitive impairment and dementia of Alzheimer's type.
Fellgiebel A; Kojro E; Müller MJ; Scheurich A; Schmidt LG; Fahrenholz F
J Geriatr Psychiatry Neurol; 2009 Mar; 22(1):3-9. PubMed ID: 19073834
[TBL] [Abstract][Full Text] [Related]
37. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
[TBL] [Abstract][Full Text] [Related]
38. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.
Kang JH; Vanderstichele H; Trojanowski JQ; Shaw LM
Methods; 2012 Apr; 56(4):484-93. PubMed ID: 22503777
[TBL] [Abstract][Full Text] [Related]
39. CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele.
Smach MA; Charfeddine B; Lammouchi T; Harrabi I; Ben Othman L; Dridi H; Bennamou S; Limem K
Neurosci Lett; 2008 Aug; 440(2):145-9. PubMed ID: 18555606
[TBL] [Abstract][Full Text] [Related]
40. No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease.
Engelborghs S; Sleegers K; Cras P; Brouwers N; Serneels S; De Leenheir E; Martin JJ; Vanmechelen E; Van Broeckhoven C; De Deyn PP
Brain; 2007 Sep; 130(Pt 9):2320-6. PubMed ID: 17586559
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]